Bioray Biotech and EdiCure Announce Strategic Collaboration to Empower Innovative Drug Development

Shanghai, February 21, 2022 /PRNewswire/ -- On the morning of February 18, 2022, BRL Medicine Inc. (hereinafter referred to as "BRL Medicine") and Clinflash Healthcare Technology (Jiaxing) Co., Ltd. (hereinafter referred to as "Clinflash"), a member company of Tigermed, held a grand strategic cooperation signing ceremony at the Shanghai headquarters of BRL Medicine.

Group Photo of Both Parties' Representatives

Attending the signing ceremony were Xi Zaixi, CEO of BRL Medicine, Gao Yang, Chief Strategy Officer, Li Wei, Vice President of Medical and Clinical Affairs, Huang Anling, Director of Intellectual Property & Marketing Department, Xiao Sa, Deputy Director of Supply Chain Management Department, Cao Yinqiu, Deputy Director of Strategic Cooperation Department, Guan Weihua, General Manager of Clinflash Healthcare Technology (Jiaxing) Co., Ltd., Leng Xiaoxia, Executive Deputy General Manager, Fan Rong, Director of Business Development, Ma Guangming, Senior Business Manager, along with other senior corporate leaders, who jointly witnessed this historic moment.

This time, based on BRL Medicine's comprehensive layout in the cell and gene therapy field, combined with Clinflash Healthcare Technology’s clinical information cloud solutions and data service technology, the two parties will carry out in-depth cooperation in the future to comprehensively improve the efficiency and quality of clinical research, accelerate the process of new drug research and market entry, and promote innovation in China's pharmaceuticals industry.

Solidify the Foundation of Cooperation, Jointly Plan a New Chapter of Development

BRL Medicine CEO Zaixi Xi (left), Clinflash Healthcare Technology (Jiaxing) Co., Ltd General Manager Weihua Guan (right)

At the signing ceremony, regarding this strategic cooperation, CEO of BRL Medicine, Zaixi Xi, stated in his speech: "We are very pleased to become a strategic partner with Clinflash Healthcare. With the mission of 'leading innovation through gene editing, developing breakthrough therapies, and benefiting all humanity,' BRL Medicine has already built and put into operation a 7,000-square-meter GMP pilot production base and formed an operational team of over 200 people with extensive experience in new drug R&D, CMC, quality control, clinical research, and commercialization. BRL Medicine is committed to becoming a global leader in cell and gene therapy companies, and currently, multiple projects have entered the global IND application stage. In the future, BRL Medicine will continue to drive rapid updates and iterations of R&D products based on patient needs and clinical feedback. With an open, shared, and win-win attitude, we will work with enterprises in the global innovative biopharmaceutical ecosystem to accelerate the transformation and implementation of innovative drugs for the benefit of patients with genetic diseases and malignant tumors worldwide! We are very pleased that BRL Medicine can establish a strategic partnership with Jiaxing Clinflash Healthcare Technology Co., Ltd. We look forward to leveraging Clinflash's advanced technology platform and resources to improve the efficiency of clinical research, guided by clinical value, and accelerate the R&D and transformation of innovative drugs. We aim to contribute Chinese strength to the global biopharmaceutical industry and help Chinese innovative pharmaceutical companies steadily move towards standardization and internationalization!"

In this regard, Guan Weihua, General Manager of Clinflash, also stated: "As a leader in cloud solutions for the clinical research field, Clinflash has been striving to provide efficient and compliant information systems and professional, high-quality services to innovative pharmaceutical companies. Our cooperation with BRL Medicine is also a process that helps us better understand the actual needs of innovative pharmaceutical enterprises, thereby continuously improving and perfecting our products. We look forward to maximizing the potential of information technology in our future cooperation, empowering clinical research, accelerating the new drug development process, and bringing more high-quality innovative products to market as soon as possible."

Scene of the bilateral symposium

Finally, a technical symposium on clinical trial information solutions was held between the two parties. At the symposium, Dr. Yang Gao, Chief Strategy Officer of BRL Medicine, and Dr. Wei Li, Vice President of Medical and Clinical Affairs, conducted in-depth discussions with Clinflash Healthcare Technology (Jiaxing) Co., Ltd. on establishing a comprehensive clinical project management system and flexibly addressing new challenges posed by drug regulatory authorities in and outside China. Strategic consensus was reached during the exchange.

In the future, the two parties will continue to deepen and expand their cooperation in clinical project research, developing a series of functions in a targeted manner to fully align with regulatory requirements both in China and internationally. This collaboration aims to support pharmaceutical companies in standardizing clinical project management and further aligning China's drug registration technical standards with international norms. Both parties firmly believe that through the close partnership between BRL Medicine and Clinflash Healthcare Technology (Jiaxing) Co., Ltd., new momentum will be injected into the upgrading of China’s pharmaceutical industry. Together, they will advance hand-in-hand to benefit patients worldwide suffering from genetic disorders and malignant tumors.